跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
CIMA-AEMPS
/
BUVIDAL 160 mg SOLUCION INYECTABLE DE LIBERACION PROLONGADA
Approved
STANDARD
BUVIDAL 160 mg SOLUCION INYECTABLE DE LIBERACION PROLONGADA
Camurus Ab
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jun 23, 2021
Approval ID
e969fcd497933fe1
Company
Camurus Ab
Type
Standard
Approval Details
Approval Id
e969fcd497933fe1
Drug Cima Aemps Name
BUVIDAL 160 mg SOLUCION INYECTABLE DE LIBERACION PROLONGADA
Register Number
1181336009
Holder Company Name
Camurus Ab
Marketing Company Name
Camurus Ab
Holder Company Detail Path
/organization/camurus-ab
Marketing Company Detail Path
/organization/camurus-ab
Authorization Date
2021-06-23
Dosage Form
SOLUCION INYECTABLE DE LIBERACION PROLONGADA
Dose
160 mg
Route Of Administration
VÍA SUBCUTÁNEA
Prescription Type
Uso Hospitalario
Commercialized
No
Company Name
Camurus Ab
Company Detail Path
/organization/camurus-ab
Company Information
Pharmaceutical Company Name
Camurus AB
Country Name
Sweden
City Name
lund,skåne,country_se
Address
Ideongatan 1A
Website
http://www.camurus.com
Active Ingredients
BUPRENORFINA
160 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jun 23, 2021
Approval ID
e969fcd497933fe1
Type
Standard
Back to CIMA-AEMPS Approvals